FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology, and aims at sub-typing breast cancer. RIL (PDLIM4) expression is measured in a patient's tumour tissue sample by the sequencing technology of the following NGS generation or by northern hybridisation methods and real-time PCR. If the RIL (PDLIM4) expression tends to decrease twice as much as its level in the normal tissues, a sub-type of a malignant breast new growth is diagnosed.
EFFECT: invention provides effective diagnostic technique for breast cancer subtype - tumours characterised by incomplete epithelial-mesenchymal transition and relatively minimally invasive.
2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SET OF SYNTHETIC OLIGONUCLEOTIDES FOR DETERMINATION OF LEVELS OF GENE PDLIM4 EXPRESSION | 2015 |
|
RU2612139C1 |
| NEW CANCER ANTIGEN FOR EARLY DETECTION OF CANCER, METHOD FOR OBTAINING, ISOLATION AND DETECTION THEREOF | 2020 |
|
RU2818471C2 |
| REAGENT KIT FOR DETECTING A MARKER OF EPITHELIAL CARCINOMAS | 2018 |
|
RU2735918C2 |
| METHOD OF USING AXL AS MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION | 2010 |
|
RU2586493C2 |
| CANCER MARKER AND THERAPEUTIC TARGET | 2008 |
|
RU2529797C2 |
| METHOD FOR PREDICTION OF THE RISK OF DEVELOPING WEB-ASSOCIATED TUMORS IN THE PATIENTS WITH ACUTE EBV-INFECTION | 2019 |
|
RU2707075C1 |
| METHOD OF DETERMINING DURATION OF RECURRENCE-FREE INTERVAL IN SEROUS OVARIAN CANCER | 2015 |
|
RU2613302C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2012 |
|
RU2521389C2 |
| METHODS FOR TREATING MALIGNANT TUMOUR WITH APPLICATION OF NOTCH SIGNAL TRANSDUCTION PATHWAY INHIBITORS | 2008 |
|
RU2584579C2 |
| METHOD OF EARLY MOLECULAR-BIOLOGICAL DIAGNOSIS OF MALIGNANT GROWTHS AND AMYOTROPHIC LATERAL SCLEROSIS | 2018 |
|
RU2706714C1 |
